Searched for
PATENT CLIFF OPPORTUNITIES
The 30% smallcap tilt: How Abakkus Flexi Cap Fund is positioning for the next rallyAbakkus Mutual Fund is strategically allocating 30% to smallcaps within its Flexi Cap Fund, identifying mispriced opportunities despite str...- Indian pharma leaving generics era behind, but the Street hasn't caught up yet: Nandan KulkarniIndian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...
- Novo Nordisk’s weight-loss drug patent loss sparks a ‘gold rush’ for generic drugmakersIndia's weight-loss drug market is seeing a major shift. Generic versions of Novo Nordisk's semaglutide are now available at lower prices. ...
- Merck & Co to create a separate cancer unit as patent cliff loomsMerck & Co is restructuring by splitting its drug division into two separate businesses. The change is designed to spotlight its fastest-gr...
- Bristol Myers lines up many launches for India with 'AI' speedBristol Myers Squibb sees India as a major growth driver. The company is investing heavily in AI to speed up drug launches and improve doct...
- Go on, pop the innovation pill: ₹5,000 cr push signals India’s shift from copy to createIndia's pharma sector is poised for innovation-led growth, fueled by patent expirations and government support. The ₹5,000-cr PRIP scheme a...
- Breaking free from the ‘frog in a well’ mindset: Manish Chokhani’s advice to retail investorsManish Chokhani urges Indian investors to explore global markets, warning against over-reliance on domestic stocks. He highlights undervalu...
- Pharma stocks: A strategic choice in today’s volatile marketWith the exception of the last two months, the Nifty Pharma index has shown a consistent uptrend over the past 18 months. It has recently s...
- 3 reasons why Indian pharma is getting ready for unstoppable growthFor Indian pharmaceutical companies, this scenario presents a distinct opportunity. Leveraging their established expertise and leadership i...
- Patent cliff can turn Indian pharma stocks into investor’s goldminePharma stocks have surged due to a 'Patent Cliff,' where numerous drug patents expire, allowing generic manufacturers, especially in India,...
- Buy Syngene International, target Rs 675: ICICI DirectBuy Syngene International at a price target of Rs 675.
- I admire Dilip Shanghvi of Sun Pharma, says Lupin’s Vinita GuptaNilesh and I complement each other and share a common passion when it comes to the company - Vinita Gupta
- US exports may drive top Indian pharma cos to grow 20% in 2013"We believe that top players of the sector will continue to grow strongly in 2013, primarily led by exports.
- Biologics worth $50 bn to lose patent protection in USA:Report"It is estimated that between 2009 and 2019, 21 biologics with a market value of over $ 50 billion will lose patent protection in the US al...
- ‘Patent cliff’ forces pharmaceuticals companies to eye new marketsCompanies like Dr Reddy’s , Ranbaxy, Glenmark and Zydus Cadila have readied a strategy to counter the scenario , which is set to become cha...
- Patent expiries: Dr Reddy's, Lupin to foray into specialty pharma, Aurobindo Pharma to focus on servicesIndia's top pharmaceutical companies are preparing for life after high revenues from expiring patents drops off at the end of this year.
- Pharma cos may have to shift business strategy due to slow growth: ReportDrug makers might have to shift their business strategy as an overcrowded US market and peaking opportunities threaten to slow down growth.
- Indian pharma companies like Ranbaxy, Dr Reddy’s & others eye $1bn generic opportunityIn the wake of patent expiries on three blockbuster drugs over the last six-seven months, an opportunity worth nearly $1.3 billion is up fo...
- Four growth drivers beyond patent for pharma companies like Sun Pharma, SanofiIt is not just Big Pharma that has to prepare for life after the 'patent cliff'' patent expiries on a slew of blockbuster drugs.
- Companies to gain as Big Pharma goes genericFaced with losses once its blockbusters start losing patents, Big Pharma is now devising strategies to counter the impact.
Load More
